Simple Plex™ Assays used to measure Human Thymus and Activation-Regulated Chemokine in Hodgkin Lymphoma patients

By Erin Christey, Simple Plex Product Manager

Optimizing therapies for patients with Hodgkin lymphoma relies upon the identification of prognostic factors that will predict outcomes and guide treatment approaches. A cross-departmental group at the Memorial Sloan Kettering Cancer Center recently published their findings on how baseline metabolic tumor volume is a predictive factor for patients with relapsed/refractory Hodgkin lymphoma.

Following standards set by the Clinical Laboratory Improvement Amendments (CLIA), they measured pre- and post-therapy levels of TARC (cysteine-cysteine thymus and activation related chemokine) with the Ella automated immunoassay platform and Simple Plex™ TARC assay. The precise and reliable method of measuring this chemokine at both low and elevated levels enabled the research group’s decision to expand its evaluation to a second cohort in the study.

Learn more about Simple Plex